Alías L, Bernal S, Barceló MJ, et al. 2011 Accuracy of marker analysis, quantitative real-time polymerase chain reaction, and multiple ligation-dependent probe amplification to determine SMN2 copy number in patients with spinal muscular atrophy. Genet. Test. Mol. Biomarkers 15 587–594

Article  PubMed  Google Scholar 

Alías L, Bernal S, Calucho M, et al. 2018 Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling. Eur. J. Hum. Genet. 26 1554–3557

Article  PubMed  PubMed Central  Google Scholar 

Anhuf D, Eggermann T, Rudnik-Schöneborn S, et al. 2003 Determination of SMN1 and SMN2 copy number using TaqMan technology. Hum. Mutat. 22 74–78

Article  PubMed  Google Scholar 

Arkblad EL, Darin N, Berg K, et al. 2006 Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul. Disord. 16 830–838

Article  PubMed  Google Scholar 

Arslan D, Inan B, Kilinc M, et al. 2023 Nusinersen for adults with spinal muscular atrophy. Neurol. Sci. 44 2393–2400

Article  PubMed  Google Scholar 

Azad AK, Huang CK, Jin H, et al. 2020 Enhanced carrier screening for spinal muscular atrophy: detection of silent (SMN1: 2 + 0) carriers utilizing a novel TaqMan genotyping method. Lab. Med. 51 408–415

Article  PubMed  Google Scholar 

Bajaj A, Mathew S, Vellarikkal SK, et al. 2019 Genomics of rare genetic diseases—experiences from India. Hum. Genomics 13 52

Article  Google Scholar 

Baranello G, Darras BT, Day JW, et al. 2021 Risdiplam in Type 1 Spinal Muscular Atrophy. N. Engl. J. Med. 384 915–923

Article  PubMed  Google Scholar 

Ben-Shachar S, Orr-Urtreger A, Bardugo E, et al. 2011 Large-scale population screening for spinal muscular atrophy: clinical implications. Genet. Med. 13 110–114

Article  PubMed  Google Scholar 

Blasco-Pérez L, Paramonov I, Leno J, et al. 2021 Beyond copy number: A new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients. Hum. Mutat. 42 787–795

Article  PubMed  PubMed Central  Google Scholar 

Bose M, Parab SD, Patil SM, et al. 2019 Exploring spinal muscular atrophy and its impact on functional status: Indian scenario. Indian. J. Public. Health 63 254–257

Article  PubMed  Google Scholar 

Brzustowicz LM, Lehner T, Castilla LH, et al. 1990 Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2–33.3. Nature 344 540–541

Article  ADS  PubMed  Google Scholar 

Burghes AH 1997 When is a deletion not a deletion? When it is converted. Am. J. Hum. Genet. 61 9–15

Article  PubMed  PubMed Central  Google Scholar 

Burghes AH and Beattie CE 2009 Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10 597–609

Article  PubMed  PubMed Central  Google Scholar 

Burnett BG, Muñoz E, Tandon A, et al. 2009 Regulation of SMN protein stability. Mol. Cell. Biol. 29 1107–1115

Article  PubMed  Google Scholar 

Burr P and Reddivari AKR 2022 Spinal muscle atrophy. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA

Butchbach MER 2021 Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development. Int. J. Mol. Sci. 22 7896

Calucho M, Bernal S, Alías L, et al. 2018 Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 28 208–215

Article  PubMed  Google Scholar 

Cancès C, Richelme C, Barnerias C, et al. 2020 Clinical features of spinal muscular atrophy (SMA) type 2. Arch. Pediatr. 27 7S18–7S22

Article  PubMed  Google Scholar 

Cartegni L and Krainer AR 2002 Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30 377–384

Article  PubMed  Google Scholar 

Cartegni L, Hastings ML, Calarco JA, et al. 2006 Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am. J. Hum. Genet. 78 63–77

Article  PubMed  Google Scholar 

Ceylan AC, Erdem HB, Sahin I, et al. 2020 SMN1 gene copy number analysis for spinal muscular atrophy (SMA) in a Turkish cohort by CODE-SEQ technology, an integrated solution for detection of SMN1 and SMN2 copy numbers and the “2+0” genotype. Neurol. Sci. 41 2575–2584

Article  PubMed  Google Scholar 

Chen X, Sanchis-Juan A, French CE, et al. 2020 Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet. Med. 22 945–953

Article  PubMed  PubMed Central  Google Scholar 

Chencheri N, Alexander G, Nugud A, et al. 2023 Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children. Muscle Nerve 68 269–277

Article  PubMed  Google Scholar 

Chiriboga CA, Swoboda KJ, Darras BT, et al. 2016 Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86 890–897

Article  PubMed  PubMed Central  Google Scholar 

Chiriboga C, Mercuri E, Fischer D, et al. 2019 P.363JEWELFISH: safety and pharmacodynamic data in patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam (RG7916) that have previously been treated with nusinersen. Neuromuscul. Disord. 29 S187

Article  Google Scholar 

Chiriboga CA, Bruno C, Duong T, et al. 2023 Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: An interim analysis from the Jewelfish study. Neurol. Ther. 12 543–557

Article  PubMed  PubMed Central  Google Scholar 

Cho S and Dreyfuss G 2010 A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes. Dev. 24 438–442

Article  PubMed  PubMed Central  Google Scholar 

Collén A, Bergenhem N, Carlsson L, et al. 2022 VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug. Discov. 21 79–80

Article  PubMed  Google Scholar 

Costa-Roger M, Blasco-Pérez L, Cuscó I, et al. 2021 The importance of digging into the genetics of SMN genes in the therapeutic scenario of spinal muscular atrophy. Int. J. Mol. Sci. 22 9029

Crawford TO, Paushkin SV, Kobayashi DT, et al. 2012 Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 7 e33572

Article  ADS  PubMed  PubMed Central  Google Scholar 

Dangouloff T, Vrščaj E, Servais L, et al. 2021 Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscul. Disord. 31 574–582

Article  PubMed  Google Scholar 

Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, et al. 2021 Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N. Engl. J. Med. 385 427–435

Article  PubMed  Google Scholar 

Darras B, Baranello G, Boespflug-Tanguy O, et al. 2023 FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA) (P7–3.009). Neurology 100 3928

Article  Google Scholar 

Day JW, Finkel RS, Chiriboga CA, et al. 2021 Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20 284–293

Article  PubMed  Google Scholar 

DiDonato CJ, Chen XN, Noya D, et al. 1997a Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene. Genome Res. 7 339–352

Article  PubMed  Google Scholar 

DiDonato CJ, Ingraham SE, Mendell JR, et al. 1997b Deletion and conversion in spinal muscular atrophy patients: is there a relationship to severity? Ann. Neurol. 41 230–237

Article  PubMed  Google Scholar 

Dobnik D, Štebih D, Blejec A, et al. 2016 Multiplex quantification of four DNA targets in one reaction with Bio-Rad droplet digital PCR system for GMO detection. Sci. Rep. 6 35451

Article  ADS  PubMed  PubMed Central  Google Scholar 

Duong T, Wolford C, McDermott MP, et al. 2021 Nusinersen treatment in adults with spinal muscular atrophy. Neurol. Clin. Pract. 11 e317–e327

Article  PubMed  PubMed Central  Google Scholar 

Eggermann K, Gläser D, Abicht A, et al. 2020 Spinal muscular atrophy (5qSMA): best practice of diagnostics, newborn screening and therapy. Med. Genet. 32 263–272

Google Scholar 

Elsheikh B, Prior T, Zhang X, et al. 2009 An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 40 652–656

Article  PubMed  Google Scholar 

Emmady PD and Bodle J 2022 Werdnig Hoffmann disease. StatPearls

Ertl HCJ 2022 Immunogenicity and toxicity of AAV gene therapy. Front. Immunol. 13 975803

Article  PubMed  PubMed Central  Google Scholar 

Fainmesser Y, Drory VE, Ben-Shushan S, et al. 2022 Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3. Neuromuscul. Disord. 32 451–459

Article  PubMed